Vaccination against HPV: Theoretical Aspects and Practical Results of Cervical Cancer Prevention

Relevance. Cervical cancer (CC) continues to be the focus of attention of oncologists all over the world due to the fact that the incidence of it over the past decades has not tended to decrease. The steady increase in morbidity, high mortality rates, and the tendency to «rejuvenate» the disease, the relatively low detection rate of the early stages of the disease due to poor results of cytological screening predetermine the search for new scientifically based approaches to solving cervical cancer problems. A promising direction for the prevention of squamous cell carcinoma and adenocarcinoma associated with human papillomavirus (HPV) is prophylactic vaccination against HPV, the need for which is due to the role of HPV infection in carcinogenesis processes.

The aim of this article is to summarize the currently available data on advances in the prevention of precancerous lesions and cervical cancer, primarily through vaccination against HPV infection.

Conclusions. The creation of vaccines for the prevention of oncogenic HPV types is a significant achievement in the biomedical research area. The successful development of a group of vaccines, which can confidently be called the vaccines of the 21st century, gives us hope that modern medicine has the potential to reduce population cancer risk and reduce the likelihood of early onset of cervical cancer. Demonstration of the efficacy and feasibility of routine HPV vaccination programs in a number of countries demonstrates encouraging progress in solving cervical cancer problems. Vaccination against HPV will not only ensure epidemiological well-being, but also lead to a decrease in morbidity and mortality from such a terrible complication of human papillomavirus infection – cervical cancer.

1. Bruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report 15 December 2016.

2. Zlokachestvennye novoobrazovaniya v Rossii v 2016 godu (zabolevaemost’ i smertnost’). Kaprin AD, Starinskij VV, Petrova GV ed. M.: MNIOI im. P.A. Gercena – filial FGU «NMICR» Minzdrava Rossii; 2018. 250 p. (In Russ.)

3. Kaprin AD, Novikova EG, Trushina OI, Grecova OP. Skrining raka shejki matki – nereshennye problemy. Nauchno-prakticheskij zhurnal «Issledovaniya i praktika v medicine». 2015; 2 (1):36– 40 (In Russ.)

4. American College of Obstetricians and Gynecologiests. ACOG Practice Bulletin number 109, December 2009:Cervical cytology screening. Obstet Gynecol. 2009; 114: 409–1420

5. Comprehensive cervical cancer control: a guide to essential practice – 2nd ed. WHO; 2014.

6. Franco EL, Harper DM. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005; 23: 2388–2394.

7. Zur Hausen H. Papillomaviruses causing cancer: Evasion from host cell control in early events in carcinogenesis. J Natl Cancer Ins. 2000; 92: 690–698.

8. Moscicki AB. HPV infections in adolescents. Disease Markers. 2007; 73: 229–34.

9. Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. British Medical Journal. 2002; 325:572.

10. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55: 244–265.

11. Syrjanen K, Syrjanen S. Papillomavirus Infections in Human Pathology. New York; 2000.

12. Prilepskaya VN. Vakcinaciya protiv VPCH-associirovannyh zabolevanij i raka shejki matki. Medicinskij sovet. 2016; 12: 120–5. (In Russ.)

13. Castellsagué X, de Sanjosé S, Aguado T et al. HPV and cervical cancer in the world. Vaccine. 2007; 25 (3): 27–219.

14. Bosch FX, Cuzick J, Schiller J, et al. HPV vaccines and screening in the prevention of cervical cancer. Vaccine. 2006; 24 (3): S1–S264.

15. Smith J, Lindsay L, Hoots B, et al. Human papilloma virus distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. International Journal of Cancer. 2007; 121: 621–32.

16. Castellsague X, Diaz M, de Sanjose S et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. Journal of National Cancer Institute. 2006; 98: 303–15.

17. Stanley M, Lowy DR, Frazer I. Vaccine. 2006; 24 (3): S106–S112.

18. Suzich JA, Ghim SJ, Palmer-Hill FJ et al. Sistemic immunization with papilloma virus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA. 1995; 92 (25): 11553–11557.

19. Koutsky LA, Ault KA, Wheeler CM et al. A cotrolled trial of a human papilloma virus type 16 vaccine. New England Journal of Medicine. 2002; 347: 1645–51.

20. Arbyn M, Simoens C, Martin-Hirsch P. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews. 2018, Issue 5. Art № CD009069 doi: 10.1002/14651858.CD009069.pub3

21. Vakcinoprofilaktika zabolevanij, vyzvannyh virusom papillomy cheloveka: feder. klinich. rekomendacii. MZ RF, Soyuz pediatrov Rossii. M.: Pediatr; 2017. 40 p.

22. Monitoring the coverage and impact of human papillomavirus vaccine – report of WHO meeting; 2010.

23. Gallagher KE, LaMontagne DS, Watson-Jones D. Status of HPV vaccine introduction and barriers to country uptake. Vaccine. 2018; 36:4761–4767.

24. Luostarinen T, Apter D, Dillner J, et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer. 2018; 142 (10): 2186–2187.

25. Namazova-Baranova LS, Chemakina DS, Vishneva EA et al. Obzor vakcinacii protiv papillomavirusnoj infekcii v mire. Pediatricheskaya farmakologiya. 2018;15(1):80–85 (In Russ.).

26. Garland SM, Kjaer SK, Muñoz N et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. CID. 2016; 63: 519–27.

27. Baldur-Felskov B, Dehlendorff C, Junge J et al. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control. 2014; 25: 915–922.

28. Kjaer SK, Nygard M, Dillner J et al. A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries. Clin Infect Dis. 2017; 66: 339–345. doi: 10.1093/cid/cix797

29. Markowitz LE, Hariri S, Lin C et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. 2013; 208: 385–393. doi: 10.1093/infdis/jit192

30. Hariri S, Bennett NM, Niccolai LM et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States – 2008–2012. Vaccine. 2015; 33: 1608–1613. doi: 10.1016/j.vaccine.2015.01.084

31. Guo F, Cofie LE, Berenson AB. Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction. Am J Prev Med. 2018; 55 (2): 197–204.

32. Paavonen J, Naud P, Salmerón J et al. HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a doubleblind, randomised study in young women. Lancet. 2009; 374: 301–14.

33. Tabrizi SN, Brotherton JM, Kaldor JM et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014; 10: 958–966. doi: 10.1016/S1473-3099(14)70841-2

34. Patel C, Brotherton J, Pillsbury A et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Euro Surveill. 2018; 23 (41).

35. Steben M, Thompson MT, Rodier C et al. A Review of the Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: 10 Years of Clinical Experience in Canada. Journal of Obstetrics and Gynaecology. 2018; 40 (12): 1635–1645. doi: 10.1016/j.jogc.2018.05.024

36. Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2–3)? Gynecologic Oncology. 2013; 130: 264–268.

37. Ghelardi A, Ghelardi F, Martella F et al. SPERANZA project: HPV vaccination after treatment for CIN2+. Gynecologic Oncology. 2018; 151 (2): 229–234. doi: 10.1016/j.ygyno.2018.08.033

38. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. N Engl J Med. 2007; 356 (19): 1928–1943. doi: 10.1056/NEJMoa061760

39. Bentley J. Colposcopic Management of Abnormal Cervical Cytology and Histology. J Obstet Gynaecol Can. 2012; 34 (12): 1188–1202.

40. World Health Organization. Human papillomavirus (HPV) and cervical cancer. Available at: https://www.who.int/en/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer Accessed: 5 May 2019.

41. Kitchener HC, Almonte M, Wheeler P et al. ARTISTIC Trial Study Group (2006). HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. British Journal of Cancer. 2006; 95: 56–61.